Summary
The RANGE trial was a phase 3, double-blind, randomised controlled trial evaluating ramucirumab (a vascular endothelial growth factor receptor 2 inhibitor) combined with docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy. The trial enrolled a large international cohort and compared clinical outcomes between the active treatment and placebo arms, providing evidence on the efficacy and tolerability of this combination regimen in a treatment-refractory population.
UK applicability
If efficacy was demonstrated, findings would inform National Health Service treatment guidelines for urothelial carcinoma; however, applicability depends on trial outcomes, cost-effectiveness within NHS constraints, and whether results are consistent with European regulatory assessments.
Key measures
Clinical efficacy endpoints (likely progression-free survival and/or overall survival), response rates, and adverse event profiles in the ramucirumab-treated versus placebo-treated arms.
Outcomes reported
As suggested by the title, this phase 3 randomised controlled trial measured efficacy and safety outcomes in patients with locally advanced or metastatic urothelial carcinoma receiving ramucirumab plus docetaxel versus placebo plus docetaxel following platinum-based chemotherapy.
Topic tags
Dig deeper with Pulse AI.
Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.